Sarah Cannon Research Institute | Strategic Alliance Partners

Stephanie L. Graff, MD, discusses the importance of using genomic risk to tailor treatment to patients with early-stage hormone receptor-positive, HER2-negative disease, the benefit of extended endocrine therapy, and ongoing research with CDK4/6 inhibitors and immunotherapy.

Stephanie L. Graff, MD, discusses the utility of extended adjuvant therapy in women with early-stage hormone receptor-positive, HER2-negative breast cancer.

Erika P. Hamilton, MD, discusses research presented at the 2019 San Antonio Breast Cancer Symposium and how the data are impacting the treatment of patients with HER2-positive breast cancer.

Denise Yardley, MD, discusses the implications of CDK4/6 inhibitors in hormone receptor-positive/HER2-negative breast cancer. 

Howard "Skip" A. Burris, III, MD, chief medical officer and president, Clinical Operations, Sarah Cannon Research Institute, 2019 ASCO president-elect, and a 2014 Giant of Cancer Care® in Drug Development, discusses the incorporation of biosimilars in oncology.

Erika P. Hamilton, MD, director, Breast Cancer and Gynecologic Research Program, Sarah Cannon Research Institute, discusses the phase II HER2CLIMB trial in metastatic HER2-positive breast cancer.

Erika P. Hamilton, MD, discusses the results of the phase III KATHERINE trial in HER2-positive breast cancer.

Erika P. Hamilton, MD, discussed several studies in the HER2-positive breast cancer space and the sequencing challenges that have emerged.

Erika P. Hamilton, MD, discusses the impact of biosimilars in oncology.

Denise Yardley, MD, discusses the impact of biosimilars on breast cancer treatment.

Erika P. Hamilton, MD, director, Breast and Gynecologic Research Program, Sarah Cannon Research Institute, discusses overcoming resistance to HER2-targeted therapy in breast cancer.

Jesus Berdeja, MD, the director of Multiple Myeloma Research at Sarah Cannon Research Institute, discusses anticipated research in the field of multiple myeloma.

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses the potential of chimeric antigen receptor (CAR) T-cell therapy in chronic lymphocytic leukemia (CLL).

Erika P. Hamilton, MD, director, Breast and Gynecologic Research Program, Sarah Cannon Research Institute, discusses the optimal duration of trastuzumab (Herceptin) in patients with HER2-positive breast cancer.

Erika P. Hamilton, MD, shares insight on the management of patients with HER2-positive breast cancer and strategies aimed at targeting treatment resistance and toxicity.

Suman Kambhampati, MD, co-director of the Blood Cancer Center at Sarah Cannon Research Institute, HCA Midwest Health, discusses the use of ropeginterferon alfa-2b in myeloproliferative neoplasms (MPNs).

Joseph F. Stilwill, MD, shares insight on the clinical benefit seen with CDK4/6 inhibitors in patients with advanced HR-positive, HER2-negative breast cancer and highlights ongoing research aimed at overcoming acquired resistance.

Stephanie L. Graff, MD, director of the Breast Program at the Sarah Cannon Cancer Institute of HCA Midwest Health, and associate director of the Breast Cancer Research Program at Sarah Cannon Research Institute, discusses patient factors used to consider optimal treatment duration of tamoxifen in patients with breast cancer.

Suman Kambhampati, MD, co-director of the Blood Cancer Center at Sarah Cannon Research Institute, HCA Midwest Health, discusses the role of interferon in the treatment of patients with myeloproliferative neoplasms.

Stephanie L. Graff, MD, discusses data surrounding escalation and de-escalation in patients with early-stage, hormone receptor–positive breast cancer.

Suman Kambhampati, MD, co-director of the Blood Cancer Center at Sarah Cannon Cancer Institute, HCA Midwest Health, discusses the patient populations that remain an unmet need in chronic lymphocytic leukemia (CLL).

Suman Kambhampati, MD, reflects on the emergence of data in chronic lymphocytic leukemia from the 2018 ASH Annual Meeting.

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses data from the 2018 ASH Annual Meeting in chronic lymphocytic leukemia (CLL).

Jesus Berdeja, MD, director of Multiple Myeloma Research at Sarah Cannon Research Institute, discusses the treatment of patients with newly diagnosed myeloma.

Howard "Skip" A. Burris, III, MD, chief medical officer, Sarah Cannon Research Institute, 2019 ASCO president-elect, and a 2014 Giant of Cancer Care® in Drug Development, discusses the impact of molecular profiling in breast cancer.

Erika P. Hamilton, MD, director, Breast and Gynecologic Research Program, Sarah Cannon Research Institute, discusses emerging therapies in HER2-positive breast cancer.

Erika P. Hamilton, MD, reflects on the latest data in HER2-positive breast cancer and additional therapies moving through the pipeline.

Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, discusses the importance of tailoring treatment approaches to the different subtypes of patients with breast cancer.

Jesus Berdeja, MD, director of Multiple Myeloma Research at Sarah Cannon Research Institute, discusses maintenance therapy in multiple myeloma.

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses the combination of frontline ibrutinib plus obinutuzumab for the treatment of patients with chronic lymphocytic leukemia.